SCHEMBL3883121

SCHEMBL3883121

COC(=O)CCc1ccc(OCc2ccc(C(F)(F)F)cc2)c(-c2ccc3cnccc3c2)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.48
CDK8 P49336 1/20 0.48
TRPV1 Q8NER1 2/20 0.42
AKT1 P31749 8/20 0.42
CDK2 P24941 7/20 0.42
PPARG P37231 2/20 0.41
ALOX5 P09917 1/20 0.41
PSEN1 P49768 1/20 0.41
LRRK2 Q5S007 2/20 0.40
IKBKB O14920 1/20 0.40
SRPK3 Q9UPE1 1/20 0.40
PPARD Q03181 1/20 0.40
PPARA Q07869 1/20 0.40
SLC2A1 P11166 1/20 0.39
SGK1 O00141 1/20 0.39
FFAR1 O14842 1/20 0.39
FFAR2 O15552 1/20 0.39
FFAR4 Q5NUL3 1/20 0.39
DGAT2 Q96PD7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3882929 0.90 FFAR4 (0.48) CCNCCDK8AKT1CDK2PPARG
SCHEMBL3886352 0.83 AKT1 (0.42) AKT1CDK2PPARAFFAR1FFAR2
SCHEMBL3894938 0.82 PPARD (0.44) AKT1CDK2PPARGALOX5PSEN1
SCHEMBL3883570 0.82 FFAR4 (0.42) ALOX5PSEN1PPARDPPARAFFAR1
SCHEMBL3882022 0.80 CCNC (0.58) CCNCCDK8LRRK2IKBKB
SCHEMBL3887117 0.78 CCNC (0.52) CCNCCDK8FFAR1FFAR4
SCHEMBL3882028 0.78 CCNC (0.49) CCNCCDK8PPARGFFAR1FFAR4
SCHEMBL3883470 0.78 CCNC (0.50) CCNCCDK8AKT1IKBKBFFAR4
SCHEMBL3887851 0.77 CCNC (0.49) CCNCCDK8IKBKBFFAR4
SCHEMBL3889538 0.75 CCNC (0.52) CCNCCDK8IKBKBFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 CCNC 2174/4885CDK8 3600/4885TRPV1 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.